Eleven biopharmaceutical companies have completed a new round of financing! (June 2)
This issue’s biopharmaceutical financing roundup covers cutting-edge tracks including AI-enabled RNA technology, in-vitro platelet regeneration, medical laser devices, microsurgical instruments, AI-powered interventional therapy, in-vivo gene editing, intelligent elderly bathing equipment, anti-microbial resistance diagnostics, universal cell therapy, precision cardiovascular treatment and brain-spinal cord interface. Eleven enterprises such as Digitalgene.AI, Xueji Biotech, Mil Medical, Yaotang Therapeutics and Shenfu Jianxing have secured fresh financing amid sustained capital inflows targeting hard-core technology and innovative therapeutics.
1. Digitalgene.AI Secures Pre-A Financing to Accelerate AI-driven RNA Medicine & Consumer Health Development
Shanghai Digitalgene.AI, an R&D firm focused on AI-powered RNA innovation, has closed its Pre-A round led by specialty nutrition biotech firm Cabio Biotech, with CICC Capital and other investors participating. Combined with prior angel proceeds, total fundraising has reached tens of millions of US dollars.
Proceeds will fund three core priorities: advancing ongoing clinical pipelines, upgrading its integrated AI+RNA R&D platform, and commercializing siRNA raw materials for consumer health to build end-to-end industrialization spanning prescription drug R&D and over-the-counter commercialization.
Built on its proprietary closed-loop R&D paradigm combining in silico AI design and in vitro wet-lab validation, the firm drastically shortens traditional RNA development cycles. Its self-developed RNA delivery platform addresses industry-wide bottlenecks around drug delivery efficiency and safety to build differentiated IP moats. Its pulmonary fibrosis program has yielded notable clinical milestones, while multiple dermatology-focused wellness pipelines are at early commercialization stages. The interdisciplinary founding team boasts full-spectrum capabilities spanning basic research to mass production.
Company founders aim to pioneer a new development model for RNA therapeutics. Investors remark the AI+RNA convergence across biopharma and beauty health stands at the cusp of explosive growth, citing the company’s one-of-a-kind core technologies and promising market prospects to drive industrial upgrade.
2. Xueji Biotech Closes Second Tranche of ~CNY300mn Series B to Fund Drug Development and Pre-IPO Preparation
On June 2, Suzhou Xueji Biotech, a pioneer in regenerative cell therapy, secured the second close of its Series B totaling nearly CNY300 million, only four months after its first tranche. New investors include SDIC Venture Capital and Hebei Industrial Investment Fund, with existing backers such as CDH Investments and Weidu Venture continuing follow-on investments; repeated top-ups from Weidu reflect robust investor confidence in its in vitro platelet regeneration platform.
Global platelet supplies rely heavily on voluntary blood donation, plagued by unstable inventory, difficult matching and infectious disease risks. Ex-vivo manufactured platelets represent a transformative fix for worldwide blood shortages. Founded in June 2021, Xueji Biotech leads China’s platelet regeneration space with proprietary directed stem cell differentiation technology, developing cell therapy and novel drug pipelines alongside peers including Yingguan Bio.
Fresh capital will support clinical trials for its core megakaryocyte injection and accelerate its platelet product to fill unmet clinical supply gaps, plus advance novel anti-aging candidates derived from platelet precursors. The firm plans to kick off Pre-IPO financing within the year to construct production facilities and expand manufacturing capacity ahead of future pipeline commercialization. Per founder Zhu Fangfang, R&D will stay anchored in real-world clinical and commercial needs to deliver diversified cell therapeutics and hit key capital market milestones.
3. Mil Medical Bags CNY100mn+ Series B to Scale Multi-scenario Medical Laser Platform
Mil Medical, a domestic developer of multi-scenario clinical laser equipment, has secured a over-100-million-yuan Series B round. The financing is led by the Greater Bay Area Venture Capital Guiding Fund under SDIC Venture Capital, joined by Nanshan Strategic Emerging Industry Investment and Shunbo Fund; incumbent investor Shenzhen Hi-Tech Investment made additional injections, with KaiCheng Capital acting as exclusive financial advisor.
One of few domestic enterprises mastering full-stack R&D and manufacturing of thulium fiber lasers, Mil achieves 100% localization of core components and overcomes technical hurdles for clinically critical 1940nm thulium laser devices, ending long-term foreign monopolies on key parts and finished products. The breakthrough slashes manufacturing costs and lead times while securing independent supply chains; its flagship products now capture over 25% of China’s domestic market with proven commercial traction. Its vertically integrated product portfolio serves urology, dermatology and general surgery with strong platform scalability.
Funds will finance IND-enabling clinical trials and commercial rollout of new flagship products, next-gen laser R&D and nationwide channel expansion. Investors highlight vast domestic substitution potential for clinical laser hardware, noting Mil’s proprietary end-to-end tech builds solid barriers to become China’s benchmark medical laser enterprise.
4. Huarong Kechuang Completes Over-CNY100mn Series A Led by Proxima Capital
Tianjin Huarong Kechuang Biotechnology, a national high-tech enterprise, has wrapped up a Series A financing exceeding CNY100 million led by healthcare-focused Proxima Capital, with Howell Capital as exclusive financial advisor.
Focused on high-end microsurgical devices and degradable biomedical materials, the firm owns patented magnesium alloy platforms. Its flagship product, Kepule V2.0 microvascular anastomosis device, resolves historic material and process bottlenecks to break overseas monopoly. Domestic microsurgery has long depended on imported anastomosis consumables, inflating clinical costs and restricting accessibility of complex soft tissue reconstruction and digit replantation procedures; the launch fills a critical domestic market blank.
New capital will consolidate its technical edge, expedite clinical registration and global commercial expansion. Sun Xiaolu, Founder of Proxima Capital, affirms the team’s sharp grasp of domestic substitution trends with clear technical and monetization blueprints for sustained institutional backing. Li Qinghua, MD of Howell Capital, comments its innovative core technology aligns with industrial upgrade needs with robust upside. Proxima Capital currently manages nearly CNY5 billion AUM focused on innovative medical technology investments.
5. Weguang Medical Secures Multi-Hundred-Million-Yuan Financing to Build AI-powered Interventional Diagnosis & Treatment Platform
China has over 330 million cardiovascular patients fueling double-digit annual growth in interventional treatment demand, with precision and intelligent upgrading as core industry priorities. Domestic interventional device developer Weguang Medical has closed a new multi-hundred-million-yuan financing round led by China-US Green Yangtze Delta Fund and Yifeng Capital, with BOC Capital and Huiyu Investment participating.
Proceeds are allocated to two core directions: global commercialization of core diagnostic tools including OCT (Optical Coherence Tomography), and accelerated R&D for AI-enabled innovative interventional pipelines. The company is strategically evolving from a single-product maker into a full-cycle AI interventional platform with a closed-loop “Diagnosis-Therapy-Assessment” ecosystem: upgraded OCT hardware paired with AI imaging analytics boosts intraoperative lesion detection accuracy and efficiency; multi-energy ablation devices fill unmet domestic therapeutic gaps; perioperative full-cycle management completes systematic clinical service coverage.
Investors regard AI-integrated interventional devices as one of China’s rare globally competitive medtech tracks, with Weguang’s end-to-end layout forming scarce competitive moats. Going forward, the firm will keep advancing technical innovation, export homegrown interventional solutions and speed up domestic substitution and global expansion.
6. Yaotang Therapeutics Raises Nearly CNY500mn Series C for One-Time-Curative In Vivo Gene Editing Drugs
On May 29, Yaotang Therapeutics, a domestic in-vivo gene-editing biotech, closed its nearly CNY500 million Series C led by Pangu Venture Capital alongside multiple top-tier healthcare investors with full follow-on support from existing shareholders.
Founded in 2021, Yaotang specializes in single-administration curative in vivo gene editing therapies for inherited disorders and intractable chronic illnesses. Its fully self-developed platform spans gene editor engineering and delivery system development with proprietary IP breaking overseas foundational tech monopolies, with six pipelines advanced into clinical development. Its lead asset YOLT-201 became China’s first LNP-based in vivo gene-editing candidate to enter pivotal registration trials in 2024; YOLT-203 obtained US FDA clearance for confirmatory clinical studies in 2025, placing Yaotang among a handful of Chinese firms with global clinical development capacity.
Lead investor Pangu Venture Capital commends its robust R&D productivity and fast clinical translation speed. Financing will fund clinical progression of core programs, construction of commercial-grade CMC production lines and new pipeline discovery to develop curative therapies for underserved diseases worldwide. Global in vivo gene editing financing stays robust as the industry enters clinical harvest phase, with leading players including Yaotang and LEXEO Therapeutics.
7. Zhijing Tech Bags Nearly CNY10mn Angel Round for Disabled Elderly Bathing Robotics Market Expansion
China’s senior care segment continues attracting venture inflows; Zhijing Tech, focused on portable smart bathing robots for disabled seniors, secured around CNY10 million in angel financing co-led by Qicheng Investment and Canadian angel investors. The company has kicked off Pre-A preparation to deploy funds for nationwide sales rollout, product iteration and next-gen bathing equipment R&D.
Per civil affairs statistics, over 40 million Chinese seniors suffer from partial or complete disability, creating massive unmet demand for professional home bathing services plagued by high operating thresholds and steep traditional pricing (CNY200–300 per session out of reach for most households). Its proprietary compact bathing robot weighs only 4.5kg, deployable within 10 minutes for single-operator use and cuts per-service cost below CNY150 to lower industry entry barriers.
Its core business model combines hardware sales plus recurring consumable revenue, complemented by caregiver training and equipment leasing to penetrate institutional markets, with over 63.7% repeat institutional purchase rate and 99% end-user satisfaction. Scaled mass production starting in 2025 has driven strong shipment growth and early profitability plus follow-on institutional investment, validating its commercial viability. The financing signals rising primary market confidence in senior care essentials and will accelerate affordable standardized domestic elderly bathing services.
8. Ruijiang Capital Leads Angel Investment in Fuchi Medical to Advance Antimicrobial Resistance Diagnostic Innovation
Ruijiang KangSheng Fund under Ruijiang Investment has led a multi-million-yuan angel investment in domestic IVD developer Fuchi Medical. Capital will fuel R&D, mass production and global commercialization of its rapid antimicrobial susceptibility testing platform, marking Ruijiang’s deepened footprint in hard-core medical biotech.
Antimicrobial resistance poses a critical global public health threat; WHO data links over 1.2 million annual fatal infections worldwide to resistant pathogens. Conventional culture-based susceptibility testing takes 2–3 days, falling far behind emergency clinical needs and driving indiscriminate empirical antibiotic use that worsens resistance, creating urgent demand for rapid precision diagnostics.
Fuchi’s founding team blends top academic credentials and industrial know-how led by Dr. Tong Benfu, a preeminent expert in infectious disease diagnostics whose core technology directly addresses traditional testing bottlenecks. Zhao Jinqiang, Chairman of Ruijiang Investment, notes its products fill global unmet clinical needs to empower domestic biotech innovation. Dr. Tong confirms new funds will accelerate commercial launch, with the team aiming to break international oligopoly and deliver China-originated solutions against global antimicrobial resistance.
9. Zhenyu Bio Closes Near-CNY100mn Financing to Advance Next-Gen Cell Therapy Pipelines
Chengdu Zhenyu Biotech has secured a nearly CNY100 million financing co-led by Chengdu Future Industry Fund and Oriza Ventures, with Renyou Investment, SJ Fund and incumbent Legend Capital participating. Proceeds prioritize clinical advancement of core assets, iterative upgrade of differentiated tech platforms and pre-commercial manufacturing buildout.
Founded in July 2023, Zhenyu develops next-generation universal cell therapies via two proprietary platforms: mRNA-LNP based in vivo CAR-T and novel therapeutic vaccine candidates, bypassing cost and accessibility flaws limiting conventional autologous cell therapy to target systemic in-vivo delivery for multiple hard-to-treat solid tumors.
Its flagship in-vivo TCR-T program CR101 demonstrates potent anti-tumor efficacy in early clinical work, receiving US FDA Orphan Drug Designation for nasopharyngeal carcinoma plus approval for translational trials at Hainan Boao West China Lecheng Hospital, making it one of China’s few clinically-stage in-vivo TCR-T assets. Key clinical milestones within three years of incorporation attract strong VC endorsement for its disruptive next-gen cell therapy path, with fresh capital speeding IND filings and commercial manufacturing construction.
10. Ruixin Medical Completes D-round Financing Worth Nearly CNY100mn to Deepen Precision Cardiovascular Therapy
Shenzhen Ruixin Intelligent Medical closed a nearly CNY100 million D-round led by Guangzhou Healthcare Industry Investment with Yuefu Fund as participant; the firm is setting up operational headquarters in Yuexiu District, Guangzhou. Industrial investment validates its proprietary technical moats and clinical translation value while funding accelerated pipeline commercialization and global market expansion.
A frontrunner in China’s AI-powered cardiovascular medtech sector, Ruixin’s integrated intelligent platform spans diagnostic assessment, functional measurement and interventional treatment with diversified product lines: flagship coronary functional evaluation tool AngioQ FA is a domestic industry benchmark alongside widely-adopted Ruixin Score; newly developed intracardiac ultrasound (ICE) completes its full-cycle clinical service loop for differentiated competitive advantages.
Rising cardiovascular prevalence in China fuels booming demand for precision interventional devices with massive domestic substitution upside for AI medtech. Multiple comparable financing rounds closed across cardiovascular AI space in the past 30 days, with Ruixin and Shukun Technology as core domestic players. Ruixin commits to clinical-demand-driven scaled commercialization to evolve into a globally competitive intelligent medtech enterprise.
11. Shenfu Jianxing Raises Over CNY300mn to Accelerate Implantable Spinal Cord Interface toward Clinical Trials
Against global unmet clinical demand for spinal cord injury treatment, the invasive neural interface sector secures major investment as Shenfu Jianxing (Shanghai) Medical Devices completes a series of angel financings exceeding CNY300 million led by Cathay Capital with follow-on from Fudan University Sci-Tech Investment. Funds support multi-center pivotal trials for its original three-in-one implantable spinal-cerebral interface, R&D base construction and global clinical development.
Available therapies for complete spinal cord injury only relieve symptoms without restoring voluntary motor function, leaving a massive global treatment gap. Its proprietary triple-function implantable platform integrates brain motor intent decoding, lesion bypass reconstruction and closed-loop spinal cord stimulation to rebuild brain-limb neural pathways and reverse paralysis at the mechanistic level.
2025 proof-of-concept clinical data shows four trial subjects regained voluntary leg movement within 24 hours post-implant, with hip/knee controllable motion achieved in as fast as seven days; robust safety and efficacy secured US FDA Breakthrough Device Designation to speed overseas regulatory review. The firm has officially kicked off nationwide multi-center registration trials. Investors cite invasive neural interface as a core global medtech innovation track, with Shenfu Jianxing’s first-mover edge and clear clinical roadmap accelerating bench-to-bedside translation to fill global treatment voids for tens of millions of nerve injury patients.
About Us
MeritsIP: Your Global Intellectual Property Partner
At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.
Stay Connected
-
- Website: https://www.meritsipglobal.com
-
- LinkedIn: Follow us on LinkedIn
-
- Email: meritsip@meritsandtree.com
© 2025 MeritsIP. All Rights Reserved.
